Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis:
The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries
Modelling to estimate the health impact of novel tuberculosis vaccines on TB burden in people living with HIV
Creating evidence to support tuberculosis (TB) national and global decision-makers in reducing the global burden of TB
Potential implications of reduced tuberculosis vaccine efficacy in those with undernutrition on overall vaccine impact in India
New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?
